Although acute pulmonary embolism is a common condition many clinicians have serious doubts about the correct treatment for individual patients. The reason for these doubts is simple; there is a lack of conclusive clinical data on which to base decisions. There are several important questions for the clinician when faced with such patients: (1) Does the patient need thrombolytic treatment? (2) How should heparin be administered? (3) Should venography with a view to venous interruption be performed routinely in patients who have suffered definite pulmonary embolism?
Is thrombolytic treatment needed?
Thrombolytic treatment is not needed in patients who have suffered minor acute pulmonary embolism or even massive pulmonary embolism (defined angiographically as greater than 50% obstruction of the pulmonary arterial bed) unless there is considerable haemodynamic embarrassment. These patients do well with heparin, which drastically reduces the risk of further embolism, while natural-lytic processes remove thrombus from the pulmonary and venous circulations.' 3 Thrombolytic treatment does not reduce early mortality23 or improve long term clinical results. 4 Subtle abnormalities of pulmonary function due to capillary damage are much less one year after the event in patients who have received thrombolytic treatment, but the clinical significance of these findings is unknown5 and probably unimportant.
Randomised trials comparing heparin and thrombolytic treatment have shown conclusively that emboli clear much more rapidly from pulmonary arteries in those patients receiving thrombolytic drugs2 3 but in these trials there was no difference in mortality. Although, theoretically, a benefit might be expected as a result of more rapid clearing of the clot from the pulmonary arteries, thrombolytic treatment has never been shown to affect mortality. This may be because no benefit exists or because the design of these trials could not be expected to produce an answer. The latter explanation is probably correct. Since the early death rate is high, survival in acute massive pulmonary embolism is a function of the time that elapses after the embolism before the patient is first seen.6 By the time referral to a centre, enrolment into the trial, and investigations such as angiography have taken place a group of " survivors" has already been selected.
It is unlikely that an adequate comparison of heparin with thrombolytic treatment, restricted to haemodynamically compromised patients seen early after embolism, will ever be performed. Firstly, the logistic problem of collecting similar groups of patients are enormous. Secondly, the knowledge that thrombolytic treatment can clear thrombus rapidly from the pulmonary arteries makes it impossible to withhold it from the patient deteriorating with heparin treatment even though, because of the way the clinical condition can alter rapidly in the early stage after embolism, some of these deteriorating patients might be expected to survive eventually without any change in treatment. The incidence of "treatment failure" (defined as clinical deterioration despite adequate treatment requiring escalation of treatment to thrombolytic medication or embolectomy) was much higher in patients receiving heparin for life threatening massive pulmonary embolism (30%) than in patients receiving thrombolytic treatment (15%). Treatment As soon as a diagnosis of pulmonary embolism is strongly suspected and while these difficult decisions are being taken, intravenous heparin should be given as a bolus (10 000 IU for the average sized adult).
How should heparin be administered?
Heparin has been available for clinical use for nearly 50 years but many physicians still have considerable doubts about the correct way to use it. The object of heparin treatment is simple: to give enough to prevent recurrent thrombosis and embolism while avoiding haemorrhagic complications. The problems arise from a lack of conclusive evidence about the best and safest method of administration, whether dosage should be arbitrary or controlled by clotting tests to achieve maximum safety combined with effectiveness, and how long the drug should be given for. These would, at first sight, seem easy questions to answer but the extent of published work on heparin treatment proves that this is not so. Studies have often been far from ideal, containing patients with a wide variety of thromboembolic disorders sometimes mixed with patients simply receiving prophylactic anticoagulation." The rate at which heparin is consumed varies with the degree of thrombosis and tends to be higher when this is extensive. ' The intricacy of these problems is well summarised by the excellent but extremely complicated study of Wilson et al. 17 Like others before them, they suggest that the main determinant of recurrence and haemorrhagic complications is the dose of heparin administered."'4 '5 In general, studies comparing intermittent (usually four hourly) injection of heparin and continuous infusion have shown that haemorrhagic complications are lower in patients having the latter, who also tend to receive lower overall dosages.' X15 16 The only study which found a higher incidence of complications with infusion is also the only one in which this group received the higher dosage. ' Since there is no convincing evidence to guide the clinician, he has to remember that standard regimens of anticoagulation are generally easy to administer and produce excellent results. The overall early mortality rate in treated acute pulmonary embolism from further embolism or haemorrhage is 3-5%7 '' and deaths due to recurring embolism after hospital discharge are extremely rare. 4 The results of the routine use of a surgical procedure with a high operative mortality rate (15% for ligation or plication of the inferior vena cava, 7% for the surgical insertion of clips to narrow and compartmentalise the lumen of the vena cava inferior'9) and a high incidence of unpleasant lower limb oedema and venous thrombosis in the later stages (40%) can never rival those figures.
The pervenous placement of filters, umbrellas, and so on in the inferior vena cava is safer than surgical ligation or plication and creates less by way of venous complications, but has problems of its own.'9 Insertion needs experience and difficulties occur in up to 15% of cases.2 The filters may migrate or may themselves embolise and are sometimes sited in the wrong place (14%). A few patients (3%) have emboli after placement. The operative mortality of the procedure is probably 1-3%. '9 Many authorities on the subject now admit that anticoagulation alone is adequate treatment for nearly all patients2' 22 and that venous interruption, preferably using a filter device (the Greenfield filter seems the easiest to use), should be reserved for patients with either definite recurrence of pulmonary embolism despite adequate anticoagulation or a high risk of emboli combined with a strong contraindication to anticoagulants. Once such a view bas been adopted routine venography becomes illogical unless one of these indications for venous interruption is present. Since such patients are rare, amounting possibly to 2% of all patients experiencing acute pulmonary embolism,'9 22 venous interruption should be carried out only in specialist centres where clinicians have the chance to build up the necessary experience to keep the risks of insertion low.
Conclusions
Thrombolytic treatment probably benefits patients who suffer a large acute pulmonary embolus but it should not be used unless the embolus causes considerable haemodynamic disturbance. In nearly all other situations thrombolytic treatment is more expensive, more dangerous, but no more effective than heparin. When heparin is given there seems to be little to choose between intermittent injection and continuous infusion. The value of coagulation tests as a guide to adjustment of heparin dosage is not proved and seems to need reassessment in the light of the recent discovery of large diurnal variations in heparin activity. Finally venography, in the setting of a proved pulmonary embolus, is unnecessary unless recurrence of embolism despite adequate anticoagulation or a strong contraindication to anticoagulants makes a venous interruption procedure
